跳至主要内容
临床试验/NL-OMON45095
NL-OMON45095已完成4 期

The Clinical Efficacy And Subclinical Effects on arterial STIFFNESS of bosentan therapy added to usual care in patients with systemic sclerosis with digital ulcers. - CEASE STIFFNESS

niversitair Medisch Centrum Groningen0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • SSc patients
  • * 18 years or older
  • * Systemic sclerosis based on the 2013 ACR/EULAR criteria
  • * Raynaud*s phenomenon (RP)
  • * A history of digital ulcer disease
  • * Assessable Pulse Wave Velocity (PWV) measurement at baseline
  • * Written informed consent;Healthy controls:
  • * 18 years or older
  • * Written informed consent

排除标准

  • SSc patients:
  • * Hypersensitivity to the active substance or to any of the excipients
  • * Moderate to severe hepatic impairment, i.e., Child-Pugh class B or C
  • * Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT), greater than 3 times the upper limit of normal
  • * Concomitant use of cyclosporine A
  • * Pregnancy
  • * Women of child-bearing potential who are not using reliable methods of contraception
  • * Significant peripheral vascular disease as the sole consequence of atherosclerotic disease due to for example diabetes, dyslipidemia, systemic hypertension, coagulopathy;Healthy controls:
  • * Comorbidities

研究者

相似试验